Necessity of In Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients with Equivocal HER2 Immunohistochemistry Results

키워드

참고문헌 (30)

1. Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.359~386 (2015)[DOI]
2. Perou CM, "Molecular portraits of human breast tumours", Nature, 406, pp.747~752 (2000)[DOI]
3. Goldhirsch A, "Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)[DOI]
4. Nielsen TO, "Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma", Clin Cancer Res, 10, pp.5367~5374 (2004)[DOI]
5. Ross JS, "The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine", Oncologist, 14, pp.320~368 (2009)[DOI]
6. Slamon DJ, "Human breast cancer: correlation of relapse and survival with amplification of the HER-2", neu oncogene, 1987, pp.235, 177~182
7. Piccart-Gebhart MJ, "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer", N Engl J Med, 353, pp.1659~1672 (2005)[DOI]
8. Perez EA, "Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31", J Clin Oncol, 29, pp.3366~3373 (2011)[DOI]
9. "NCCN clinical practice guidelines in oncology breast cancer version 4"[URL]
10. Denduluri N, "Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario clinical practice guideline", J Clin Oncol, 34, pp.2416~2427 (2016)[DOI]
11. Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
12. Wolff AC, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, 2007, pp.25, 118~145
13. Moelans CB, "Current technologies for HER2 testing in breast cancer", Crit Rev Oncol Hematol, 80, pp.380~392 (2011)[DOI]
14. Stenzinger A, "Quantitative analysis of diagnostic guidelines for HER2-status assessment", J Mol Diagn, 14, pp.199~205 (2012)[DOI]
15. Valent A, "Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management", Cancer Genet, 206, pp.37~41 (2013)[DOI]
16. Wishart GC, "PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2", Br J Cancer, 107, pp.800~807 (2012)[DOI]
17. DeLong ER, "Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach", Biometrics, 44, pp.837~845 (1988)[DOI]
18. Dendukuri N, "Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis", CMAJ, 176, pp.1429~1434 (2007)[DOI]
19. Amin MB, "AJCC Cancer Staging Manual. 8th ed." (2016), Springer International Publishing
20. Tchrakian N, "New ASCO", CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers, 2016, pp.468, 207~211
21. Odicino FE, "HER-2", neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization, 2008, pp.18, 14~21
22. Gao FF, "Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases", Am J Clin Pathol, 141, pp.102~110 (2014)[DOI]
23. Kim S, "Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in breast cancer cells", Anticancer Res, 31, pp.3767~3773 (2011)
24. Lee SK, "Distinguishing low-risk luminal a breast cancer subtypes with Ki-67 and p53 is more predictive of long-term survival", PLoS One, 10, pp.e0124658~ (2015)[DOI]
25. Sjogren S, "The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry", J Natl Cancer Inst, 88, pp.173~182 (1996)[DOI]
26. Shapira I, "P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency", Crit Rev Oncol Hematol, 88, pp.284~292 (2013)[DOI]
27. Lee HJ, "Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer", Br J Cancer, 112, pp.103~111 (2015)[DOI]
28. Fan YS, "HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO", CAP practice guideline, 2016, pp.155, 457~462
29. Papouchado BG, "Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility", Am J Surg Pathol, 34, pp.767~776 (2010)[DOI]
30. Parmar C, "Radiomic feature clusters and prognostic signatures specific for Lung and Head & Neck cancer", Sci Rep, 5, pp.11044~ (2015)[DOI]

관련 논문AI추천